|1.||Stridsberg, Mats: 8 articles (08/2013 - 03/2003)|
|2.||Mahata, Sushil K: 5 articles (04/2010 - 01/2004)|
|3.||Marksteiner, Josef: 5 articles (03/2008 - 02/2002)|
|4.||Blennow, Kaj: 3 articles (07/2013 - 12/2007)|
|5.||Zetterberg, Henrik: 3 articles (07/2013 - 12/2007)|
|6.||Humpel, Christian: 3 articles (03/2008 - 02/2002)|
|7.||Adlassnig, Christine: 3 articles (01/2004 - 11/2002)|
|8.||Kaufmann, Walter A: 3 articles (01/2004 - 02/2002)|
|9.||Mattsson, Niklas: 2 articles (01/2012 - 12/2007)|
|10.||Camu, William: 2 articles (05/2011 - 12/2009)|
|1.||Carcinoid Tumor (Carcinoid)
01/01/1995 - "In contrast, strong chromogranin B and secretogranin II immunoreactivity was found in rectal carcinoids, in which chromogranin A was rarely expressed. "
06/01/1997 - "We investigated polysiaN-CAM immunoreactivity in a range of neuroendocrine lung tumours: 15 typical carcinoids, 21 atypical carcinoids, 2 large cell neuroendocrine carcinomas and 12 small cell lung carcinomas were selected on a morphological basis and by their immunoreactivity for chromogranin A and B and secretogranin II. A progressive loss of chromogranin expression, particularly of chromogranin B, was paralleled by the up-regulation of polysiaN-CAM in histologically more aggressive tumours (P = 0.001). "
03/01/1994 - "In 17 prostatic carcinomas with pronounced neuroendocrine differentiation and in a case of prostatic carcinoid, chromogranin B was the major component whereas chromogranin A and secretogranin II were virtually absent in poorly differentiated (grade III) tumours. "
11/01/1998 - "The aim of the present study was to investigate immunohistochemically the distribution of secretoneurin, a novel 33 amino acid peptide, in comparison to chromogranin A, chromogranin B, and secretogranin II in carcinoids of the appendix. "
01/01/1995 - "In 44 patients with carcinoid tumours, 17 patients with sporadic endocrine pancreatic tumours and 11 patients with endocrine pancreatic tumours and the multiple endocrine neoplasia 1 syndrome, plasma measurements revealed elevated chromogranin A levels in 99%, elevated chromogranin B in 88%, elevated chromogranin C in 6% and elevated pancreastatin in 46% of the patients. "
01/01/1995 - "Identification of a new chromogranin B fragment (314-365) in endocrine tumors."
06/01/2013 - "Lower cytoplasmic chromogranin B (CHGB) expression (p = 0.03) was associated with malignant tumors and metastasis. "
03/01/1994 - "Neuroendocrine differentiation in prostatic cancer is most likely to be associated with a poor clinical outcome; thus, chromogranin B appears to be a useful marker in the histopathological diagnosis of these neoplasms."
11/30/2010 - "Circulating concentrations of chromogranin B-like immunoreactivity (CgB-LI) are not elevated in non-neoplastic diseases and measurements of CCB, the COOH-terminal fragment of CgB, may be useful as a biochemical marker for neuroendocrine differentiation in lung tumors. "
06/01/2007 - "One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. "
09/01/2001 - "Evidence that the chromogranin B fragment 368-417 extracted from a pheochromocytoma is phosphorylated."
12/31/1992 - "Sorting of chromogranin B into immature secretory granules in pheochromocytoma (PC12) cells."
04/25/1991 - "Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing."
11/01/1988 - "In benign pheochromocytomas, all three antigens were found consistently; whereas in two of three malignant pheochromocytomas, chromogranin B was absent. "
06/01/2007 - "Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B."
|4.||Neuroendocrine Tumors (Neuroendocrine Tumor)
02/01/2000 - "Although chromogranin A (CgA) is widely distributed in neuroendocrine tumors, the distribution of chromogranin B (CgB) has not been elucidated. "
11/01/1991 - "A neuroendocrine tumor containing predominantly chromogranin B (secretogranin I)."
04/01/2015 - "Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression."
10/01/2004 - "Sixty-three neuroendocrine tumors positive for one or more immunohistochemical marker of neuroendocrine differentiation (chromogranin A, chromogranin B, synaptophysin, secretogranin II, neuron-specific enolase) were selected for the study and consisted of 34 typical carcinoids (15 pulmonary, 11 ileal, 4 gastric, and 4 rectal), 19 PETs, and 10 pheochromocytomas (4 sporadic, 3 MEN-2, 2 neurofibromatosis type 1, and 1 VHL). "
|5.||Schizophrenia (Dementia Praecox)
01/01/2007 - "The Chromogranin B (CHGB) gene has been proposed as a candidate gene for predisposition to schizophrenia due to its location on the genome, the evidence of genetic studies, and its functional role in schizophrenia. "
01/01/2007 - "Further evidence that the chromogranin B gene confers predisposition to schizophrenia: a family-based association study in Chinese."
07/01/2004 - "Association between chromogranin b gene polymorphisms and schizophrenia in the Japanese population."
11/01/2002 - "Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia."
05/03/2002 - "Using functional and positional evidences, chromogranin B was selected as a candidate gene for schizophrenia. "
|5.||Phosphopyruvate Hydratase (Enolase)
|8.||superoxide dismutase 1